Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00253084
Status:
COMPLETED
Last Update Posted:
2019-10-29
First Post:
2005-11-11
Brief Title:
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinsons Disease
Sponsor:
Impax Laboratories LLC
Organization:
Impax Laboratories LLC
Study Overview
Official Title:
A Randomized Double-Blind Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the clinical efficacy of IPX054 to immediate-release carbidopa-levodopa in subjects with Parkinsons disease
Detailed Description:
IPX054 contains two different drugs called levodopa and carbidopa in one tablet
levodopa turns into a material called dopamine in your brain The dopamine helps to improve the symptoms of your Parkinsons disease
carbidopa belongs to a group of medicines called aromatic amino acid decarboxylase inhibitors It helps levodopa work more effectively by slowing the speed at which levodopa is broken down in your body
levodopa turns into a material called dopamine in your brain The dopamine helps to improve the symptoms of your Parkinsons disease
carbidopa belongs to a group of medicines called aromatic amino acid decarboxylase inhibitors It helps levodopa work more effectively by slowing the speed at which levodopa is broken down in your body
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None